Notice: This company has been marked as potentially delisted and may not be actively trading. TRACON Pharmaceuticals (TCON) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsDividendEarningsHeadlinesInsider TradesTrends Get the Latest News and Ratings for TCON and Related Stocks Enter your email address to receive the latest news and analysts' ratings for TRACON Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up TCON Analyst Ratings Over TimeTypeCurrent Forecast3/8/24 to 3/8/251 Month Ago2/7/24 to 2/6/253 Months Ago12/9/23 to 12/8/241 Year Ago3/9/23 to 3/8/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)2 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$60.00$60.00$60.00$80.00Forecasted Upside186,235.40% Upside186,235.40% Upside186,235.40% Upside1,519.43% UpsideConsensus RatingHoldHoldHoldModerate Buy Remove Ads TCON Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History TCON Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table TRACON Pharmaceuticals Stock vs. The CompetitionTypeTRACON PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.82 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside186,235.40% Upside32,850.58% Upside16.54% UpsideNews Sentiment RatingNeutral NewsSee Recent TCON NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails7/1/2024HC Wainwright2 of 5 starsE. WhiteSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/21/2023Jonestrading1 of 5 stars Reiterated RatingBuy ➝ Hold8/15/2023Robert W. Baird2 of 5 stars Lower TargetOutperform ➝ Outperform$140.00 ➝ $60.00+937.70%5/11/2023Maxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower Target$160.00 ➝ $60.00+322.53%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:52 PM ET. TCON Forecast - Frequently Asked Questions What is TRACON Pharmaceuticals' forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for TRACON Pharmaceuticals is $60.00, with a high forecast of $60.00 and a low forecast of $60.00. Should I buy or sell TRACON Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TCON shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCON, but not buy additional shares or sell existing shares. Does TRACON Pharmaceuticals's stock price have much upside? According to analysts, TRACON Pharmaceuticals's stock has a predicted upside of 186,235.40% based on their 12-month stock forecasts. Do Wall Street analysts like TRACON Pharmaceuticals more than its competitors? Analysts like TRACON Pharmaceuticals less than other "medical" companies. The consensus rating for TRACON Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TCON compares to other companies. Stock Forecasts and Research Tools Related Companies TFF Pharmaceuticals Stock Forecast eFFECTOR Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:TCON) was last updated on 3/8/2025 by MarketBeat.com Staff From Our PartnersA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
